Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002389647 | SCV002701656 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-05-29 | criteria provided, single submitter | clinical testing | The p.I497V variant (also known as c.1489A>G), located in coding exon 9 of the PDGFRA gene, results from an A to G substitution at nucleotide position 1489. The isoleucine at codon 497 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Labcorp Genetics |
RCV003526177 | SCV004314624 | uncertain significance | Gastrointestinal stromal tumor | 2023-07-31 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1773730). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function. This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 497 of the PDGFRA protein (p.Ile497Val). |